Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

International Cancer Genome Consortium for Medicine Launches

The International Cancer Genome Consortium (ICGC) announced plans to launch the ICGC for Medicine (ICGCmed), a new phase of the consortium that will link...

FDA Grants Orphan Designation to Iomab-B for Older Patients With AML

The U.S. FDA granted orphan drug designation to Iomab-B for the treatment of relapsed/refractory acute myeloid leukemia (AML) prior to hematopoietic cell transplantation in...

IMWG Updates Myeloma-Related Renal Impairment Management Recommendations

The International Myeloma Working Group (IMWG) has updated its recommendations for the diagnosis and management of myeloma-related renal impairment. According to the new document,...

FDA Approves New Genetic Therapy for Hemophilia A

The U.S. FDA approved Kovaltry™ antihemophilic factor (recombinant), an unmodified, full-length factor VIII compound, for the treatment of hemophilia A in children and adults....

FDA Approves New Formulation of Melphalan

The U.S. FDA approved a new formulation of melphalan injection for use as a high-dose conditioning treatment prior to hematopoietic cell transplantation in multiple...

CDC Issues New Guidelines Aimed at Reducing Opioid Addiction Risk

The Centers for Disease Control and Prevention (CDC) released updated guidelines for prescribing opioids for chronic pain (outside of active cancer and palliative and...

FDA Approves Ibrutinib as Front-Line Therapy in CLL

The U.S. FDA approved ibrutinib as a first-line treatment for patients with chronic lymphocytic leukemia (CLL). The approval was based on the results of...

FDA Approves First Coagulation Factor–Albumin Fusion Protein for Hemophilia B

The U.S. Food and Drug Administration (FDA) approved coagulation factor IX (recombinant), albumin fusion protein, also known as albutrepenonacog alfa, for use in children...

FDA Issues Recommendations to Reduce the Risk of Zika Virus Transmission Through Blood and...

The U.S. FDA announced new safety recommendations to reduce the risk of transmission of the Zika virus through human cell and tissue donations. The...

FDA Providing $2 Million in New Grants for Rare Disease Research

The U.S. FDA’s Office of Special Medical Programs/Office of Orphan Products Development (OSMP/OOPD) has launched a new grants program that will provide $2 million...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.